CryoPort Company Profile (OTCMKTS:CYRX)

About CryoPort (OTCMKTS:CYRX)

CryoPort logoCryoport, Inc. (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients. The Company's Cryoport Express Solution includes a cloud-based logistics operating platform, which is branded as the Cryoportal. The Company's Cryoport Express Solutions are made up of the Cryoportal software platform, Cryoport Express Shippers, Cryoport Express Smart Pak data loggers and its life sciences cold chain logistics expertise. The Cryoportal is used by the Company, its clients and its business partners to automate the entry of orders, prepare customs documentation, and to facilitate status and location monitoring of shipped orders while in transit.

Industry, Sector and Symbol:
  • Sector: Industrials
  • Industry: Marine Logistics
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CYRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $232.43 million
  • Outstanding Shares: 24,674,000
Average Prices:
  • 50 Day Moving Avg: $7.66
  • 200 Day Moving Avg: $4.71
  • 52 Week Range: $1.80 - $9.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.32 million
  • Price / Sales: 22.52
  • Book Value: $0.63 per share
  • Price / Book: 14.95
  • EBIDTA: ($6,680,000.00)
  • Net Margins: -63.77%
  • Return on Equity: -48.00%
  • Return on Assets: -41.35%
  • Average Volume: 212,445 shs.
  • Short Ratio: 2.1

Frequently Asked Questions for CryoPort (OTCMKTS:CYRX)

What is CryoPort's stock symbol?

CryoPort trades on the OTCMKTS under the ticker symbol "CYRX."

How were CryoPort's earnings last quarter?

CryoPort Inc (OTCMKTS:CYRX) announced its quarterly earnings results on Monday, August, 15th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.09. The company earned $1.90 million during the quarter, compared to the consensus estimate of $1.43 million. CryoPort had a negative net margin of 63.77% and a negative return on equity of 48.00%. View CryoPort's Earnings History.

Where is CryoPort's stock going? Where will CryoPort's stock price be in 2017?

2 brokers have issued 1 year price targets for CryoPort's shares. Their forecasts range from $4.50 to $5.50. On average, they anticipate CryoPort's share price to reach $5.00 in the next year. View Analyst Ratings for CryoPort.

Who are some of CryoPort's key competitors?

Who are CryoPort's key executives?

CryoPort's management team includes the folowing people:

  • Richard G. Rathmann, Independent Chairman of the Board
  • Jerrell W. Shelton, President, Chief Executive Officer, Director
  • Robert Steven Stefanovich, Chief Financial Officer, Treasurer, Corporate Secretary, IR Contact Officer
  • Robert J. Hariri M.D., Ph.D., Director
  • Richard J. Berman J.D., Independent Director
  • Ramkumar Mandalam Ph.D., Independent Director
  • Edward J. Zecchini, Independent Director

How do I buy CryoPort stock?

Shares of CryoPort can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CryoPort's stock price today?

One share of CryoPort stock can currently be purchased for approximately $9.42.

MarketBeat Community Rating for CryoPort (OTCMKTS CYRX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about CryoPort and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CryoPort (OTCMKTS:CYRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00

Analysts' Ratings History for CryoPort (OTCMKTS:CYRX)
DateFirmActionRatingPrice TargetDetails
6/16/2017Cowen and CompanyInitiated CoverageOutperform$5.50View Rating Details
6/1/2017Needham & Company LLCBoost Price TargetBuy$3.50 -> $4.50View Rating Details
2/12/2016AegisLower Price TargetBuy$8.00 -> $4.00View Rating Details
(Data available from 9/19/2015 forward)


Earnings History for CryoPort (OTCMKTS:CYRX)
Earnings by Quarter for CryoPort (OTCMKTS:CYRX)
Earnings History by Quarter for CryoPort (OTCMKTS CYRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q217($0.16)($0.14)$1.90 million$2.00 millionViewN/AView Earnings Details
8/15/2016Q117($0.19)($0.28)$1.43 million$1.90 millionViewListenView Earnings Details
6/27/2016Q416($0.02)($0.26)$1.60 millionViewN/AView Earnings Details
2/8/2016Q316($0.28)($0.42)$2.20 millionViewN/AView Earnings Details
8/6/2015Q116($0.44)($0.42)$1.40 millionViewN/AView Earnings Details
2/5/2015($0.02)($0.03)ViewN/AView Earnings Details
11/13/2014($0.02)($0.05)ViewN/AView Earnings Details
8/1/2014($0.02)($0.05)ViewN/AView Earnings Details
5/20/2014($0.02)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CryoPort (OTCMKTS:CYRX)
Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.72 EPS


Dividend History for CryoPort (OTCMKTS:CYRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CryoPort (OTCMKTS:CYRX)
Insider Trades by Quarter for CryoPort (OTCMKTS:CYRX)
Insider Trades by Quarter for CryoPort (OTCMKTS:CYRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/26/2016Jerrell SheltonCEOBuy1,000$1.99$1,990.00View SEC Filing  
8/19/2016Robert StefanovichCFOBuy1,000$1.95$1,950.00View SEC Filing  
8/18/2016Jerrell SheltonCEOBuy7,000$1.88$13,160.00View SEC Filing  
11/20/2015Jerrell SheltonCEOBuy6,000$2.32$13,920.00View SEC Filing  
8/26/2015Jerrell SheltonCEOBuy12,000$2.90$34,800.00View SEC Filing  
8/14/2015Jerrell SheltonCEOBuy23,500$3.09$72,615.00View SEC Filing  
2/11/2015Jerrell SheltonCEOBuy2,400$0.56$1,344.00View SEC Filing  
11/25/2014Jerrell SheltonCEOBuy3,400$0.47$1,598.00View SEC Filing  
11/20/2014Jerrell SheltonCEOBuy10,800$0.40$4,320.00View SEC Filing  
11/18/2014Jerrell SheltonCEOBuy9,836$0.43$4,229.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CryoPort (OTCMKTS:CYRX)
Latest Headlines for CryoPort (OTCMKTS:CYRX)
DateHeadline logoETFs with exposure to CryoPort, Inc. : September 19, 2017 - September 19 at 5:43 PM logoCryoPort, Inc. :CYRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 18 at 5:41 PM logoCYRX: Raising Price Target on CAR-T Opportunity - August 16 at 6:06 PM logoCryoport Launches - Cryoport. Certified. Cool. - August 15 at 6:27 PM logoCRYOPORT's (CYRX) CEO Jerry Shelton on Q2 2017 Results - Earnings Call Transcript - August 12 at 5:10 PM logoCryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma - August 8 at 5:28 PM logoFeatured Company News – Novartis Ropes in Cryoport for a Three-Year Contract to Provide Cryogenic Logistics Support for Commercialization of CTL019/CD19 CAR-T Cell Therapy - July 27 at 6:05 PM logoCryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia - July 25 at 5:41 PM logoCryoPort, Inc. :CYRX-US: Earnings Analysis: Q1, 2017 By the Numbers : July 21, 2017 - July 21 at 7:26 PM logoFDA Panel Votes To Approve CTL019, Positive Implications for CYRX - July 19 at 6:53 PM logoCryoport Continues to Strengthen Sales Team with Appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services - July 13 at 7:03 PM logoCryoPort Inc (CYRX) Rating Reiterated by Cowen and Company - June 17 at 9:16 AM logoCryoPort Inc (CYRX) Now Covered by Cowen and Company - June 16 at 7:00 PM logoCryoPort Inc (CYRX) Research Coverage Started at Cowen and Company - June 16 at 5:34 PM logoCowen and Company Begins Coverage on CryoPort Inc (CYRX) - June 16 at 4:22 PM logoCryoPort Inc (CYRX) Rating Increased to Hold at ValuEngine - May 12 at 6:30 PM logoCYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter - May 9 at 4:38 PM logoInvestor Network: Cryoport, Inc. to Host Earnings Call - May 4 at 4:47 PM logoCryoport Revenue Grows by 74%, Driven by Biopharma - May 4 at 4:47 PM logoCryoport to Report First Quarter 2017 Financial Results on May 4th, 2017 - April 24 at 9:07 AM logoCryoPort Inc (CYRX) Now Covered by Needham & Company LLC - April 3 at 10:04 PM logoCryoport Announces Pricing of Public Offering of Common Stock - March 28 at 12:19 PM logoCryoPort's stock tumbles on heavy volume after share offering prices at deep discount - March 28 at 12:19 PM logoCryoport Announces Proposed Public Offering of Common Stock - March 27 at 4:29 PM logoCryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016 - March 13 at 4:45 PM logoCryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016 - March 13 at 4:45 PM logoQ4 2016 Cryoport Inc Earnings Release - After Market Close - March 13 at 12:16 PM logoCryoport to Report Financial Results for the Three and Nine Months Ended December 31, 2016 on March 13th, 2017 - March 2 at 9:57 AM logoCryoport Introduces CryoStork Next Flight Out Cryogenic Logistics Solution for the Reproductive Health Market - March 1 at 1:14 PM logoCryoport Launches the "CoBRA Index" for a Comprehensive Measure of Activity in the Regenerative Therapy Space - February 28 at 4:50 PM logoCryoport to Support ProMab Biotechnologies' CAR-T Cell Preclinical Services - January 17 at 8:33 AM logoCryoport (CYRX) Announces its Validated cCyogenic Logistics Solutions are Supporting Gradalis Clinical Trials - January 3 at 6:22 PM logoCryoport Supports Gradalis' Vigil® Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers - January 3 at 12:37 PM logo8:32 am CryoPort announces its validated cryogenic logistics solutions are supporting Gradalis clinical trials to evaluate its investigational Vigil engineered autologous tumor cell cellular immunotherapy tech for use in cancer treatments - January 3 at 12:37 PM logoMoffitt Cancer Center Taps Cryoport As Exclusive Cryogenics Logistics Provider - December 21 at 5:25 PM logoCRYOPORT, INC. Files SEC form 10-Q, Quarterly Report - November 15 at 7:01 AM logoCryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017 - November 14 at 4:46 PM logoQ2 2017 Cryoport Inc Earnings Release - After Market Close - November 14 at 8:18 AM logoCryoport to Report Second Quarter Fiscal 2017 Financial Results on November 14th - November 7 at 4:22 PM logoCryoport Completes Warrant Tender Offer - November 4 at 12:08 PM logoCryoport Supporting Over 100 Clinical Trials - October 25 at 9:24 AM logoCryoport Wins 2016 Cold Chain Global Forum Excellence Award - October 4 at 9:27 AM logo"The Science Behind Logistics" Webinar, Hosted by Cryoport - September 30 at 9:35 AM logoCryoport to Present at 2016 Cell & Gene Meeting on the Mesa - September 29 at 4:26 PM logoCRYOPORT, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat - September 24 at 9:13 AM logoCryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules … - September 22 at 4:40 PM logoCryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process - September 22 at 4:40 PM logoCryoport Provides Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline - September 12 at 9:25 AM logoCryoport (CYRX), Heat Biologics (HTBX), KCAS Commence Temperature Impact on Biomarkers Study - August 30 at 5:58 AM logoCryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials - August 29 at 4:43 PM



CryoPort (CYRX) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff